Chen DY, et al. – In a cohort of 3,750 patients with type 2 diabetes mellitus (T2DM) and acute coronary syndrome (ACS) or acute ischemic stroke (AIS), researchers assessed the cardiovascular outcomes of vildagliptin using data from the Taiwan National Health Insurance Research Database. For this investigation, they assessed clinical results by comparing 1,250 subjects receiving vildagliptin with 2,500 propensity score–matched subjects. Investigators observed that treatment with vildagliptin was not linked to increased risk of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and heart failure hospitalization among patients with T2DM following a recent ACS or AIS.